Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Administered HS-10360 in Healthy Subjects.

NCT04986436 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04986436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04986436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Administered HS-10360 in Healthy Subjects.
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2021
Completion date
June 30, 2022
Enrollment
76 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy